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Abstract
Introduction: Chronic obstructive pulmonary disease (COPD), characterized by a progressive deterioration of lung function caused primarily
by the inhalation of toxic substances, is a leading cause of morbidity and mortality worldwide. Current treatment options for the
management of its symptoms include the use of bronchodilators and glucocorticoid agents that are not universally beneficial and which are
associated with limitations. Phosphodiesterase-4 (PDE4) inhibitors are a novel class of antiinflammatory agents being developed for COPD
treatment. 
Aims: The purpose of this article is to review the clinical potential of roflumilast, a PDE4 inhibitor currently in phase III clinical trials, in the
management of patients with COPD. 
Evidence review: Phase II studies indicate that roflumilast can be given orally once daily. Preliminary evidence from two phase III,
randomized, double-blind, placebo-controlled studies suggest that roflumilast improves or stabilizes lung function, as measured by forced
expiratory volume in 1s and 6 s (FEV1 and FEV6), forced vital capacity (FVC), and peak expiratory flow (PEF) in patients with COPD.
Improvements in COPD exacerbation rate were also reported in these trials. Quality of life, as measured by the St George’s Respiratory
Questionnaire, also improved with roflumilast treatment. Clinical studies to date suggest that roflumilast is well tolerated. 
Clinical potential: Current evidence supports the use of roflumilast in the management of COPD as shown by improvements in patients’
symptoms and quality of life, and good tolerability profile. Its once-daily oral dosing regimen is unique among current therapies for COPD.
This potential and the place of roflumilast in the stepwise management of the disease need to be confirmed as further evidence is published.
Additional evidence will also be welcome to determine if its mechanism of action moderates the progression of lung function deterioration. 
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Outcome measure Emerging evidence
Patient-oriented evidence
Number of acute exacerbations of COPD Dose-dependent decrease in exacerbation rate
Disease-oriented evidence
Lung function as measured by FEV1, FEV6, FVC, PEF Roflumilast improves or stabilizes lung function
FEV1, forced expiratory volume in 1s; FEV6, forced expiratory volume in 6s; FVC, forced vital capacity; PEF, peak expiratory flow; QOL, quality of life; SGRQ, St George’s Respiratory Questionnaire.
QOL as measured by SGRQ Statistically significant improvements in SGRQ scores
Core evidence proof of concept summary for roflumilast in chronic obstructive pulmonary diseaseScope, aims, and objectives
Roflumilast (ALTANA Pharma AG), a phosphodiesterase-4 (PDE4)
inhibitor, is being developed for the management of chronic
obstructive pulmonary disease (COPD) and asthma. Its once-daily
oral administration may be advantageous in the treatment of these
respiratory diseases. Pharmacologically, the PDE4 inhibitors
represent a new class of antiinflammatory agents. Preliminary data
from phase III clinical trials evaluating roflumilast in the
management of patients with COPD are available. Another PDE4
inhibitor, cilomilast (GlaxoSmithKline), has also been evaluated for
patients with COPD.
The purpose of this article is to review unmet needs in the
management of patients with COPD, and the clinical potential of
roflumilast based on the available evidence.
Methods
The English language medical literature was reviewed for
appropriate articles relating to roflumilast for the treatment of
COPD. The search terms were “roflumilast,” “APTA 2217,” “B9302-
107,” “BY 217,” “Daxas,” and “BYK 20869,” and the following
databases were searched  during January and February, 2005: 
• PubMed, www.ncbi.nlm.nih.gov/entrez 
• EMBASE, www.datastarweb.com
• Database of Abstracts of Reviews of Effectiveness (DARE), NHS
Economic Evaluations Database (NHSEED), Health Technology
Assessment (HTA), www.york.ac.uk/inst/crd/darehp.htm   
• NHS HTA, www.ncchta.org
• National Guidelines Clearinghouse, www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk
• Cochrane Database of Systematic Reviews, www.cochrane.org
• Clinical Evidence, www.clinicalevidence.com
No date limitations were placed on the search and only studies in
patients with COPD were included. Abstracts from the American
Thoracic Society (ATS) and the European Respiratory Society (ERS)
meetings from 2001 to 2004 were also reviewed using the same
search terms to identify any studies that have not yet been
published in full. Thirty-one abstracts with results from randomized
controlled trials were identified.
The levels of evidence identified from the literature searches are
summarized in Table 1 (see Editorial Information on inside back cover).
Disease overview
COPD, a progressive respiratory disease characterized by gradual
loss of lung function and airflow obstruction that is not fully
reversible, is a leading cause of morbidity and mortality worldwide.
In developed countries, it has been estimated that COPD occurs in
4–10% of the population (Halbert et al. 2003; Pauwels & Rabe
2004). However, since COPD definitions differ among clinicians and
diagnosis does not generally occur early in the disease course,
these figures are probably an underestimation of its true incidence.
Currently, COPD is the fourth leading cause of death in the USA
(NHLBI 2005), while the World Health Organization (WHO) ranks it
as the fifth most common cause of death worldwide (WHO 2005).
It is estimated that COPD will be the third leading cause of death
globally by the year 2020 (Murray & Lopez 1997; NHLBI 2005). 
Unlike other chronic conditions such as heart disease and cancer,
mortality of COPD continues to increase (GOLD/WHO/NHLBI
2004). This is influenced by both the lack of early recognition of the
disease and poor prevention strategies. Although symptoms may
be absent in early COPD, as it progresses, chronic inflammation
produces reduced airflow and hyperinflation that can lead to
dyspnea, chronic cough, sputum production, and wheezing. The
impact on the ability to perform activities of daily living can be
significant in those who experience dyspnea.
The chronic lung inflammation that is responsible for COPD is
primarily caused by inhalation of toxic substances, with cigarette
smoking being the most important risk factor. In general, the
disease is diagnosed in patients over 40 years of age. However, in
the USA, COPD is often diagnosed in 30–40 year olds. This earlier
age of diagnosis is most likely the result of an earlier exposure to
inhaled toxins because smoking occurs at an earlier age in the US
population (Briggs 2004). 
Although the costs associated with COPD differ among reporting
countries (Halbert et al. 2003), they are all significant. The total
estimated costs in 2002 in the USA were $US32.1 billion, with
$US18 billion in direct costs (NHLBI 2005). In the UK, the total
annual cost of COPD has been estimated to be £982 million (NICE
2004). Estimated costs associated with sickness benefit and
working days lost are over £1.5 billion per year in the UK (1996
estimation) (GOLD/WHO/NHLBI 2004). 
The Confronting COPD International Survey attempted to quantify
the burden of disease and morbidity in patients with COPD
(Rennard et al. 2002). Almost 13% of participants reported at least
one hospitalization in the previous year, and nearly 14% reported
requiring emergency care. Again, it is expected that these
estimates of the true burden of COPD are low.
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Number of records
Category Full papers Abstracts
Initial search
records excluded
records included
19
17
2
62
31
31a
Additional studies identified 0 N/A
Level 1 clinical evidence  2 0
Level 2 clinical evidence 0 31b
Level ≥3 clinical evidence
trials other than RCT
case reports
0
0
0
0
Economic evidence 0 0
aStudy results presented at two meetings were reviewed together.
bStudy design and quality cannot be assessed from abstract.
N/A, not available; RCT, randomized controlled trial.
Table 1 | Evidence base included in the review
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COPD is described as a process of chronic inflammation that
results in narrowing of the bronchi. The inflammatory process
initiates other changes that affect pulmonary function, including
mucous gland hypertrophy, goblet cell hyperplasia, peribronchiolar
fibrosis, and thickening of the pulmonary vasculature (NICE 2004).
The inflammatory changes of COPD differ from that of asthma. In
asthma the inflammatory process is primarily a CD4+ T-cell-driven
eosinophilia, whereas in COPD, the inflammatory process includes
an increase in the numbers and/or activity of CD8+ T cells,
macrophages, and neutrophils (Fig. 1) (Sturton & Fitzgerald 2002).
Therapies that interrupt or prevent the inflammation are ideal
candidates for modifying these inflammatory diseases.
Nonselective PDE inhibitors, such as theophylline, increase cyclic
adenosine monophosphate (cAMP) producing bronchial smooth
muscle relaxation and suppression of the inflammatory response.
Most recent research has found that theophylline does not exert
PDE inhibition to a pharmacodynamically or clinically meaningful
extent (only 5–10% PDE inhibition at therapeutic serum levels);
adenosine-A2 antagonism and histone deacetylase stimulation
appear to be the more dominant modes of action (Soto & Hanania
2005). Additionally, the widespread use of theophylline in the
management of COPD is limited by its narrow therapeutic index
and potential for drug–drug interactions. Further research into PDE
inhibition has led to the identification of at least 11 PDE enzymes
(Lipworth 2005). Current research is focused on targeting these
specific isoenzymes.
PDE4 is found in inflammatory and immune cells and is the primary
enzyme responsible for the regulation of metabolism and
inactivation of cAMP in these cells as well as in airway smooth
muscles. Inhibition of PDE4 has been associated with relaxation of
airway smooth muscle, suppression of the activation of
inflammatory cells, and modulation of pulmonary nerves (Fig. 2)
(Sturton & Fitzgerald 2002; Spina 2003; Lipworth 2005). In bronchial
biopsies, PDE4 inhibition has been linked to a decrease in the
number of CD8+ lymphocytes, macrophages, and neutrophils
(Gamble et al. 2003). Both in vitro and in vivo data indicate PDE4
inhibition produces antiinflammatory activity in cells (e.g.
neutrophils) linked to COPD airway inflammation (Soto & Hanania
2005). PDE4 inhibitors therefore offer a novel antiinflammatory
mechanism of action that differs from steroidal antiinflammatory
medications.
Current therapy options
Guidelines for the management of COPD have been published by
several different organizations. The WHO and the National Heart
Lung and Blood Institute have joined together to form the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) and
published initial guidelines in 2001 with annual review and updates
(GOLD/WHO/NHLBI 2004). The ATS and the ERS have also
published a position paper on COPD (ATS/ERS 2005). In addition,
the National Institute for Health and Clinical Excellence (NICE) in
England and Wales recently released guidelines for the
management of patients with COPD (NICE 2004). All of these
guidelines review prevalence, diagnosis, and management, and,
although each differs in the specific classification of patients with
COPD, they all recommend managing stable COPD with a
stepped-care approach.
Currently there is no cure for COPD and no pharmacologic
intervention is able to alter the rate of lung function decline.
Treatment goals include smoking cessation, reducing the risk of
further disease progression, management of symptoms, improving
physiologic function, and limiting disease complications
(GOLD/WHO/NHLBI 2004; ATS/ERS 2005) 
Smoking cessation
The only COPD intervention that has demonstrated a reduction in
the decline in lung function is smoking cessation (Sutherland &
Cherniak 2004), which can alter the course of airflow limitation or
diminish its progression (GOLD/WHO/NHLBI 2004). However,
because smoking is often a very difficult habit to break, it is
recommended that patients receive both counseling and
pharmacologic intervention to support them during the withdrawal
process. All the guidelines recommend smoking cessation as one of
the single most important interventions in COPD
(GOLD/WHO/NHLBI 2004; NICE 2004; ATS/ERS 2005). Avoidance
of other known respiratory irritants, such as occupational fumes and
dusts, and biomass fuels, is also recommended. Although smoking
cessation is an important goal, interventions are not effective for all
individuals with COPD, thus other therapies must be used to
manage the symptoms of the disease, reduce the frequency and
severity of exacerbations, and improve exercise tolerance. 
Symptom management
Shortness of breath is the symptom that is most often treated,
since it is most closely related to quality of life and health status
(GOLD/WHO/NHLBI 2004; NICE 2004; ATS/ERS 2005). Treatment
of complications, such as exacerbations and hypoxemia, include
providing oxygen and managing exacerbations with antibiotics,
glucocorticoids, and bronchodilators. Treatment options for COPD
include bronchodilators and antiinflammatory agents, the former
are central to the symptomatic management of patients with COPD
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Fig. 1 | Inflammatory process in chronic obstructive pulmonary disease 
Fig. 2 | Effects of phosphodiesterase-4 inhibition
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Drug class Route of
administration
Potential adverse effects Advantages Disadvantages
Beta2 agonists
Short-acting
Fenoterola
Albuterol (salbutamol)
Terbutaline
Long-acting
Formoterol
Salmeterol
Inhaledb Tachycardia, hypokalemia,
skeletal muscle tremor,
prolongation of QTc interval,
headache, hyperglycemia
Central to the management of COPD
Short-acting agents can be used on an “as needed” basis;
rapid onset of action
Reduce breathlessness, improve dyspnea, fatigue and FEV1
Regular use of long-acting agents more effective and
convenient that short-acting agents
Long-acting agents reduce night awakenings
Regular use of long-acting agent improves health status
Long-acting agents more
costly
Patient must be able to
use inhaler device
effectively
Anticholinergics
Short-acting
Ipratropium
Oxitropiuma
Long-acting
Tiotropium
Inhaled Dry mouth,
blurred vision
Regular use of long-acting agent improves health status
Improves exercise tolerance, dyspnea, and fatigue
Increases FEV1 and FVC, improves wheezing and dyspnea
Patient must be able to
use inhaler device
effectively
Combination short-acting beta2 agonist/anticholinergic
Fenoterol/ipratropiuma
Salmeterol/ipratropium
Inhaled Same as individual
components
Greater and more sustained improvement in FEV1 than with
single agents
Patient must be able to
use inhaler device
effectively
Methylxanthines
Aminophylline 
Theophylline
Oral Tachycardia, nausea,
vomiting, tachyarrhythmia,
seizures, headaches, CNS
stimulation, hypokalemia,
hyperglycemia
Improve exercise tolerance, FEV1, FVC, health status, lung
volume, and dyspnea
Narrow therapeutic index
Potential for significant
adverse effects and drug
interactions
Glucocorticoids (inhaled)
Beclomethasone
Budesonide
Fluticasone
Triamcinolone
Inhaled Cough, dysphonia, oral
thrush
Regular use reduces frequency of exacerbations and
improves health status
Does not modify long-term
decline in FEV1
Minimal effect on airway
responsiveness
Patient must be able to
use inhaler device
effectively
Combination long-acting beta2 agonist/glucocorticoid 
Formoterol/budesonidea
Salmeterol/fluticasone
Inhaled Same as individual
components
Combination therapy more effective than individual agents  Patient must be able to
use inhaler device
effectively
Glucocorticoids (systemic)
Prednisone
Methylprednisolone
Oral Steroid myopathy, adrenal
suppression, osteoporosis
No evidence of long-term
benefit
Systemic adverse effects
associated with long-term
oral use
aNot available in the USA.
bAlbuterol available as an oral formulation.
CNS, central nervous system; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity.
Table 2 | Pharmacologic agents used in the management of chronic obstructive pulmonary disease  (COPD) (GOLD/WHO/NHLBI 2004;
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(Table 2). At present (due to availability), the inhaled route of drug
administration is preferred for the management of COPD. This route
allows the direct application of a medication to the desired site of
action with a lower dose and a reduced risk of systemic adverse
events.
The stepwise approach to the treatment of patients with COPD, as
suggested by GOLD, is outlined in Table 3. Similar approaches are
found in the guidelines issued by NICE (2004) and ATS/ERS (2005).
Bronchodilators
Bronchodilators, including short- and long-acting beta2 agonists,
anticholinergic agents, and theophylline relax smooth muscles in
the airway, improve lung emptying during tidal breathing, and
increase forced expiratory volume in 1s (FEV1). These agents have
also been shown to improve exercise tolerance in patients with
COPD. Although bronchodilators improve symptoms and health-
related quality of life (HRQOL), their use has not demonstrated
statistically significant improvements in exacerbation rates
(GOLD/WHO/NHLBI 2004; NICE 2004; ATS/ERS 2005). Beta2
agonists and anticholinergic agents are preferred over the use of
theophylline in the management of COPD. These agents also
reduce static and dynamic hyperinflation; this pharmacodynamic
property may explain the clinical benefits beyond changes in FEV1
(i.e. reduction in breathlessness) (NICE 2004).
Because short-acting bronchodilators have a rapid onset of activity,
they can be used effectively as rescue medications. The long-acting
bronchodilators should generally be reserved for maintenance
therapy (GOLD/WHO/NHLBI 2004; NICE 2004; ATS/ERS 2005). As
a rule, their slower onset of action (with the exception of formoterol)
minimizes their usefulness in acute situations. 
Theophylline and its derivatives are not available in an inhaled
formulation and must be taken orally for chronic use. However,
high doses are often required, which can be associated with
significant toxicities (see Table 2). Additional mechanisms of
action have been attributed to theophylline, including
antiinflammatory effects and activation of histone deacetylases
(Barnes 2003). The clinical importance of these additional
mechanisms has not been established (GOLD/WHO/NHLBI 2004;
NICE 2004; ATS/ERS 2005). 
The oral slow-release preparations of theophylline have been
shown to have a positive effect on FEV1, lung volume, dyspnea,
HRQOL, and exercise endurance (GOLD/WHO/NHLBI 2004).
However, significant adverse events and clinically significant
drug–drug and drug–disease interactions limit their usefulness in
the clinical setting. Additionally, there are no published data to
support any effect of theophylline on the exacerbation rate
(GOLD/WHO/NHLBI 2004; NICE 2004; ATS/ERS 2005). 
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Stage of COPD Characteristics Management strategy
At risk Chronic symptoms (cough, sputum production)
Exposure to risk
Normal spirometry
Avoidance of risk factors
Influenza vaccination
Mild FEV1/FVC <70%
FEV1 ≥80% predicted
With or without symptoms
Avoidance of risk factors
Influenza vaccination
Short-acting bronchodilator as needed
Moderate FEV1/FVC <70%
50% ≤FEV1 <80% predicted
With or without symptoms
Avoidance of risk factors
Influenza vaccination
Short-acting bronchodilator as needed
Regular treatment with one or more long-acting bronchodilators
Severe FEV1/FVC <70%
30% ≤FEV1 <50% predicted
With or without symptoms
Avoidance of risk factors
Influenza vaccination
Short-acting bronchodilator as needed
Regular treatment with one or more long-acting bronchodilators
Addition of inhaled corticosteroids if repeat exacerbations
Very severe FEV1/FVC <70%
FEV1 <30% or FEV1 <50% predicted with
chronic respiratory failure
Avoidance of risk factors
Influenza vaccination
Short-acting bronchodilator as needed
Regular treatment with one or more long-acting bronchodilators
Addition of inhaled corticosteroids if repeat exacerbations
Long-term oxygen for respiratory failure
Exacerbations Inhaled bronchodilators, theophylline, and systemic (preferably oral) glucocorticoids
are effective treatments for exacerbations of COPD 
Airway infection may be treated with antibiotics
FEV1, forced expiratory volume in 1s; FVC, forced vital capacity.
Table 3 | Pharmacologic management of chronic obstructive pulmonary disease (COPD) (adapted from GOLD/WHO/NHLBI 2004)
 Glucocorticoids
Glucocorticoids have activity at multiple points in the
inflammatory cascade; however, their beneficial effects in patients
with COPD are less impressive than in those with asthma.
Glucocorticoids have minimal effects on neutrophils and
macrophages, which are central to the inflammatory destruction
associated with COPD (see Fig. 1) (Sturton & Fitzgerald 2002). In
patients with chronic COPD, inhaled glucocorticoids produce a
small increase in postbronchodilator FEV1 and a small decrease in
bronchial reactivity (GOLD/WHO/NHLBI 2004; NICE 2004;
ATS/ERS 2005). In addition to their effect on FEV1, administration
of inhaled corticosteroids has been associated with a positive
impact on HRQOL and a decrease in exacerbation frequency,
particularly in patients with more advanced disease
(GOLD/WHO/NHLBI 2004; NICE 2004; ATS/ERS 2005). Although
the impact on airway responsiveness is less than optimal, the
decreases in exacerbations and improvements in health status
make inhaled glucocorticoids an option for those patients with
frequent exacerbations and those with more severe disease. It is
important to note that controversy regarding the use of
glucocorticoids exists and individual studies have reported
differing responses to their use (Alsaeedi et al. 2002; Highland et
al. 2003; Bonay et al. 2005).
Glucocorticoids are also available as oral agents. However, due to
the preponderance of adverse effects associated with their long-
term oral administration they are reserved for the management of
acute exacerbations. Administration of corticosteroids via the
inhaled route can also result in systemic absorption and associated
adverse events; however, these are considerably less frequent than
with oral administration. 
Combination products
Combination therapy may be beneficial in patients with COPD.
Although beta2 agonists, anticholinergic agents, and theophylline
are all bronchodilators, each class has a different mechanism of
action. Therefore, combining medications from different
pharmacologic classes may improve symptoms in patients with
COPD and minimize the development of adverse events.
Combinations of a beta2 agonist and an anticholinergic agent, a
beta2 agonist and theophylline, an anticholinergic agent and
theophylline, and a long-acting beta2 agonist and an inhaled
corticosteroid have shown effectiveness in clinical studies and may
be beneficial in patients who require an increase in pharmacologic
support (NICE 2004). Preparations of beta2 agonists in combination
with either an anticholinergic agent or glucocorticoid are
commercially available (see Table 2). 
Other therapies
There are other, less frequently used, treatments that have not
shown consistent evidence of benefit in patients with COPD.
Mucolytics, alpha trypsin augmentation, leukotriene receptor
antagonists, maintenance antibiotic administration,
immunoregulators, respiratory stimulants, and vasodilators have
either not shown consistent benefit or have an unattractive benefit
to risk ratio in patients with COPD (GOLD/WHO/NHLBI 2004; NICE
2004; ATS/ERS 2005). 
Unmet needs
As with most diseases, there are many opportunities for
improvement in the management of patients with COPD. Despite
the effectiveness of current pharmacologic therapies, the ideal
agent has yet to be developed. Currently available treatments do
not alter the progressive decline in lung function: rather they
mitigate symptoms and/or reduce complications
(GOLD/WHO/NHLBI 2004). Clearly, there is a need for treatments
that can slow the progression of pulmonary disease, even if the
process cannot be fully reversed. Although the role of inflammation
in the pathogenesis of COPD has been identified, traditional inhaled
and/or oral antiinflammatory agents have not demonstrated a
significant impact on the progression of COPD (Sturton & Fitzgerald
2002; Lipworth 2005). Oral administration of corticosteroids is
associated with an unacceptable risk to benefit ratio in most
patients, therefore only the inhaled route of administration is
routinely used and, as stated above, these agents have minimal
effect on FEV1 and their use is thus reserved for patients with more
severe COPD. There remains a need for antiinflammatory/disease-
modifying therapy for the treatment of patients with COPD.
Beyond the absence of curative therapy, current treatment options
have inherent limitations. Many of the orally available treatments
are associated with significant adverse events. In most cases, the
potential for adverse events outweighs the clinical benefit that
could be derived from their long-term use as an oral agent. Thus,
the successful use of oral therapies in the management of COPD
has been met with limited success, and patients must use inhaled
therapies as the foundation of their treatment. Although many
patients can effectively use this type of formulation, others may
have physical limitations (e.g. as a result of arthritis) that preclude
their effective use. Additionally, the use of inhaled therapies can be
a time-consuming process that requires diligent attention to
administration technique to achieve optimal benefit. Inhaled
pharmacotherapy requires patient counseling and education, not
only at the initial visit, but also on an ongoing basis to determine
whether the use of these treatments is optimal. 
Adherence to therapy has been identified as another problem in
patients with COPD. Because the goal of therapy is symptom relief,
adherence to treatments for COPD would be expected to be high.
However, adherence to bronchodilator therapy has been relatively
poor; clinical studies evaluating patient adherence to therapy report
an adherence rate between 40 and 70% (Make 2003). Factors
associated with this poor adherence include administration
technique-related errors and poorly perceived benefits of therapy. 
Identification of an oral agent that produces beneficial effects
(decreased disease progression and antiinflammatory effects) with
a good tolerability profile would be a valuable addition to the
available treatment options. The use of simplified regimens might
also improve patient adherence to therapy and subsequently
improve quality of life and decrease frequency of exacerbations.
Outcomes achieved with roflumilast in
clinical development
Roflumilast is an orally active PDE4 inhibitor in phase III clinical
development that shows promise in patients with COPD. Its
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mechanism of action may result in an improved risk to benefit
profile for long-term use. 
Since no treatment is currently available to alter the course of
COPD, evaluations of interventions must focus on symptom
improvement and functional status. Measurements of the
effectiveness of a pharmacologic agent used in the management of
stable COPD include changes in FEV1, exercise tolerance,
improvements in quality of life and HRQOL, frequency of
exacerbations, and dyspnea (Aaron et al. 2002; de Torres et al.
2002; Desikan et al. 2002; Domingo-Salvany et al. 2002; Fan et al.
2002; Jones 2002; Miravitlles et al. 2002; Wyrwich et al. 2003). The
importance of the various outcomes differs depending on the
judgment of the individual using or interpreting the data. 
Despite being a disease-oriented outcome rather than a patient-
oriented outcome, improvement in FEV1 is often used as a standard
measure of therapeutic effect because it is easy to measure.
Consequently, it tends to be the measure that is used by clinicians
to evaluate the effectiveness of treatments for COPD. Often FEV1 is
used to indicate the presence or absence of dyspnea and to infer
quality of life changes. However, studies have shown that patients
may experience improvement in dyspnea without a corresponding
change in FEV1 (GOLD/WHO/NHLBI 2004; NICE 2004; ATS/ERS
2005). For example, bronchodilators as a group produce relatively
small changes in FEV1 yet they remain the cornerstone of COPD
therapy because of their positive effects on other measures of
symptom management, such as breathlessness and dyspnea. It is
therefore important to recognize that other, more patient-centered,
measures of treatment outcome should be used to better assess
treatment effectiveness for an individual patient, in addition to FEV1. 
Quality of life measures offer a patient perspective on treatment
effects and disease symptoms. Improvement in symptoms,
including exercise tolerance and dyspnea, can be linked to
perceived improvements in quality of life and HRQOL. HRQOL
measures include the ability to conduct activities of daily living;
therefore, these tools are often excellent predictors of patient
acceptance of a therapy. Many quality of life tools are available; the
most commonly used instruments in COPD are summarized in
Table 4. Unfortunately, the ideal assessment tool for measurement
of COPD symptoms and quality of life has not yet been developed,
and each tool has its strengths and weaknesses (de Torres et al.
2002; Desikan et al. 2002; Jones 2002; Wyrwich et al. 2003).
Currently there is no consensus delineating the most appropriate
HRQOL tool for use in patients with COPD.
Preliminary data from two phase III, randomized, parallel-group,
double-blind, placebo-controlled clinical trials evaluating
roflumilast in patients with COPD are available. The larger of the
two, the RECORD study, included 1411 patients (FEV1 of 30–80%
of predicted with reversibility of <12%) (O’Donnell et al. 2004a,b;
Rabe et al. 2004a,b). Patients enrolled in this trial received either
placebo or roflumilast 250 or 500mcg once daily for 24 weeks. The
second study included 516 patients (FEV1/FVC ≤70%,
postbronchodilator FEV1 35–75% of predicted, and FEV1
reversibility <12% and <200 mL) who received either roflumilast
250 or 500 mcg or placebo once daily for 26 weeks (Leichtl et al.
2002). Outcomes measured included lung function, exacerbation
rate, quality of life, and tolerability. In addition, there is phase I
evidence for outcomes related to the pharmacokinetic properties of
roflumilast.
These results from clinical development give an indication of the
effectiveness of roflumilast against key outcomes and areas of
unmet need in COPD management.
Once-daily dosing
Evidence from roflumilast pharmacokinetic studies conducted in
healthy volunteers support once-daily oral administration (Anon.
2004). Roflumilast is metabolized in the liver and its primary active
metabolite, roflumilast N-oxide, is responsible for much of its
pharmacodynamic activity (Huennemeyer et al. 2002a). Following
administration of roflumilast 500mcg to 18 healthy volunteers, the
half-life of the parent compound was approximately 14 h (range
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Tool  No. of items MCSD Strengths Weaknesses
Medical Outcomes
Study Short Form 36
(SF-36)
36 items covering 8 domains of
health based on WHO definitions
of health
3–5 points Generic
Good measure of general health
Can be self-administered or interviewer administered
Can be administered over the phone
Quick to administer (5min)
Not disease specific
Chronic Respiratory
Questionnaire (CRQ)
20 items covering 4 subscales 0.5 units Disease specific for chronic airflow limitation
Broadly measures physical and emotional function
Good reproducibility, validity, and responsiveness
Most responsive measure of change in HRQOLa
Individualized questions
Not standardized
Relatively long to administer
(15–25min)
St George’s
Respiratory
Questionnaire (SGRQ)
76 items covering 3 subscales 4 units Standardized; no individualized questions
Can be self- or interviewer administered
Intermediate to administer (10 min)
Scoring pattern opposite of
SF-36 and CRQ; lower
numbers indicate better
overall health
HRQOL, health-related quality of life; MCSD, minimal clinically significant difference; WHO, World Health Organization.
aThis has been questioned because of study design flaws.
Table 4 | Commonly used tools to measure quality of life in patients with chronic obstructive pulmonary disease (de Torres et al. 2002;
Desikan et al. 2002; Jones 2002; Wyrwich et al. 2003) 9–22.8 h) (Manegold et al. 2002a), thus supporting once-daily
dosing. Additionally, it does not appear that the timing of drug
administration affects the pharmacokinetics of roflumilast, since the
pharmacokinetics of both the parent drug and its active metabolite
were similar when administered in either the morning or the evening
(Hauns et al. 2003). This is in direct contrast to the oral
administration of glucocorticoids; morning administration of oral
corticosteroids is recommended to mimic the diurnal pattern of
endogenous steroids.
Dosing is simplified further, as there were no effects on the area
under the curve (AUC) of roflumilast or its major active metabolite
when 500 mcg was administered under either fed or fasted
conditions in healthy subjects (Hauns et al. 2002). 
Lung function
Measurement of pulmonary function in the clinical studies included
FEV1, forced expiratory volume in 6 s (FEV6), peak expiratory flow
(PEF), and forced vital capacity (FVC) (Leichtl et al. 2002; O’Donnell
et al. 2004a,b; Rabe et al. 2004a,b). Although FEV1 measurement
was reported in both phase III clinical trials (Table 5), other
measures of pulmonary function were not consistently included in
the initial study reports, making interpretation of findings difficult.
Based on the preliminary data, however, changes in pulmonary
function tests support roflumilast having a dose-dependent
response curve.
Both doses of roflumilast improved FEV1 significantly (P≤0.0001)
compared with placebo and FEV6 improved significantly (P=0.0051)
versus baseline in those treated with roflumilast 500 mcg/day for 24
weeks (O’Donnell et al. 2004a,b; Rabe et al. 2004a,b). Additionally,
roflumilast improved or stabilized FVC, and PEF was rated
significantly better according to patient diaries (Leichtl et al. 2002).
Exacerbation rate
There is evidence from phase III studies that roflumilast has a
positive effect on exacerbation rate, a disease-oriented, secondary
outcome. Compared with placebo, roflumilast decreased mean
exacerbation rate by 8–9% at a dose of 250 mcg/day, and by
34–48% at 500mcg/day (Table 6) (Leichtl et al. 2002; O’Donnell et
al. 2004a; Press release 2004). In a 26-week study, the mean rate
of exacerbations per patient was 1.03 in recipients of the lower
dose (n=576), and 0.75 in those receiving the higher dose (n=555),
compared with 1.13 in the placebo group (n=280; P=0.0029)
(O’Donnell et al. 2004a; Press release 2004). Data from the second
study is weaker as the number of exacerbations in both treatment
arms was very low.
Quality of life
Evidence from the RECORD study indicates roflumilast has a
positive impact on quality of life, a patient-oriented outcome (Table
7). There was a greater reduction in total St George’s Respiratory
Questionnaire (SGRQ) total score with roflumilast, indicating
improved quality of life compared with placebo. Although the
changes in total score were greater with both doses of roflumilast
than with placebo and the difference was significant (P≤0.025), no
minimal clinically significant difference in reduction of SGRQ score
was achieved by either dose. 
Tolerability and safety
Information gathered during the RECORD trial indicates that
roflumilast 250 and 500 mcg were both well tolerated (Bateman et
al. 2004). The most frequent drug-related adverse event reported
(as assessed by the investigator) was diarrhea, occurring in 2% of
the 250 mcg group (n=576) and 6% of the 500 mcg group (n=555;
statistical significance not reported). Other adverse events reported
for patients in the 500mcg group included nausea (6%), abdominal
pain (3%), weight loss (2%), headache (2%), and dizziness (2%).
Overall, this profile is promising, with relatively low rates of adverse
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Reference Treatment (mcg) n FEV1 (mL) FEV6 (mL) PEF (L/min)b FVC (mL)b
O’Donnell et al.
2004b; Rabe et al.
2004a
Placebo 280 NR NR NR NR
Roflumilast 250  576 74±18a 95±24 NR NR
Roflumilast 500 555 97±18a 135±25 NR NR
Leichtl et al. 2002 Placebo  172 57b NR 2b –64b
Roflumilast 250  175 93b NR 9b –3b
Roflumilast 500  169 109b NR 10b 19b
aImprovement in least-squares means ± SEM compared to placebo, P≤0.0001.
bChange in least-squares means from baseline. 
FEV1, forced expiratory volume in 1s; FEV6, forced expiratory volume in 6s; FVC, forced vital capacity; NR, data not reported; PEF, peak expiratory flow.
Table 5 | Improvements in lung function with roflumilast observed in phase III studies
Table 6 | Observed decrease in exacerbation rate with
roflumilast
Exacerbation rate (% reduction vs placebo)
Roflumilast 250mcg Roflumilast 500mcg
O’Donnell, et al. 2004a;
Press release 2004
(n=1411)
93 4
Leichtl et al. 2002
(n=516)
84 831
events compared with some of the other COPD treatment
modalities (theophylline, glucocorticoids). The incidence and cause
of weight loss will require additional research. Low body mass
index and fat-free mass have been associated with increased
morbidity and mortality from respiratory disease (Kilduff et al. 2003;
Sutherland & Cherniack 2004). 
Evidence is also available from an additional 516 patients with
COPD (Bredenbröker et al. 2002). Drug-related adverse events
were transient and generally subsided with continued treatment. No
severe or serious adverse events were considered to be related to
roflumilast. Common adverse events in the placebo group (n=172)
and the roflumilast 500 mcg group (n=69), respectively, were
headache (2 vs 4%), abdominal pain (1 vs 3%), nausea (2 vs 3%),
and diarrhea (0 vs 3%) (Lipworth 2005). 
Neither of the phase III studies revealed clinically significant
changes in electrocardiogram (ECG) parameters or vital signs
(Bredenbröker et al. 2002; Bateman et al. 2004). An additional study
of roflumilast 500mcg daily in 12 healthy volunteers evaluated the
impact of roflumilast on cardiac function and found no statistical or
clinically significant differences between placebo- and roflumilast-
treated patients with respect to changes in cardiac output, ECG,
blood pressure, pulse rate, or heart rate corrected total
electromechanical systole (Bethke et al. 2001). 
Drug interaction potential
In studies evaluating possible drug interactions, roflumilast was not
found to interact significantly with warfarin, inhaled salbutamol,
inhaled budesonide, or erythromycin (Weimar et al. 2001;
Huennemeyer et al. 2002a; Hauns et al. 2004a,b). In addition, the
pharmacokinetics of roflumilast are not significantly influenced by
smoking (Huennemeyer et al. 2002b). This lack of pharmacokinetic
interactions offers an advantage of roflumilast treatment over
theophylline, which is also available as an oral formulation. Use of
theophylline is limited as a result of its toxicity and potential for drug
interactions.
Pending data
The OPUS trial (1-year) is expected to be completed later in 2005
with data available in 2006. OPUS includes patients similar to those
participating in the trials already reported in COPD; patients aged
≥40 years with clinically stable COPD (FEV1/FVC ratio
postbronchodilator ≤70%, FEV1 ≤50% of predicted, no long-term
oxygen therapy) were eligible for enrollment. The study is designed
to determine whether administration of roflumilast results in changes
in the exacerbation rate, affects quality of life, or has an economic
impact on the management of patients with COPD (OPUS 2005). 
Resource utilization
The costs associated with the management of COPD continue to
increase; direct medical and indirect costs (associated with
premature morbidity and mortality) are considerable. At least one-
third of patients with COPD report an inability to work or working
time loss associated with their disease (Rennard et al. 2002).
According to 2002 Medicare data, healthcare expenses for patients
with COPD were almost 2.5 times those of other patients (NHLBI
2005). Disease that is not well controlled places patients at risk of
developing exacerbations, many of which translate to increased
healthcare spending for hospitalization (Vermiere 2002). In one
study, approximately 90% of the costs associated with an
exacerbation related to hospitalization (Oostenbrink & Rutten-van
Molken 2004). Beyond the actual economic costs of these
hospitalizations, the hospital stays themselves are associated with
increased mortality, especially in those >65 years and those who
require admission to an intensive care unit (Afessa et al. 2002;
Almagro et al. 2002). 
Since a considerable portion of the expenditures related to COPD
is associated with the management of disease exacerbations,
treatments that can reduce the number experienced would be
expected to decrease costs. Preliminary evidence indicates that
roflumilast 500 mcg results in a 34% decrease in exacerbations
compared with placebo. This decrease may directly reduce
hospitalization costs, as well as indirectly decreasing the economic
burden caused by loss of work for both patients and their
caregivers, and the costs associated with premature morbidity. The
OPUS trial may provide additional evidence on the economic
impact of roflumilast use.
Patient group/population
Roflumilast has the potential to be used in a large segment of the
COPD population. COPD is one of the leading causes of morbidity
and mortality, occurring in approximately 10% of the population in
the developed world (Halbert et al. 2003). Most patients with COPD
are over 45 years of age and have other comorbid disease states,
which complicate therapy because of the need for additional
medications and the potential for physical/cognitive limitations.
Age can also affect the pharmacokinetics of medications. However,
although the area under the plasma concentration curve for
roflumilast was higher in healthy volunteers aged 45–64 years than
in volunteers aged 22–30 years, the difference was not clinically
important and no dosage adjustment is recommended in older
patients (Manegold et al. 2002b). 
The once-daily oral administration of roflumilast will offer patients an
alternative to inhaled therapies and medication regimens that
require more frequent dosing. The effectiveness of inhaled therapies
is dependent upon correct techniques and the ability to self-actuate
devices without significant difficulty. As patients age, the use of
inhalers may become more difficult, not only because of physical
limitations associated with aging, such as arthritis, but also because
of cognitive decline that some may experience. Use of an oral agent,
like roflumilast, may obviate these issues in patients with COPD.
Likewise, this group of patients usually has declining renal function
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Table 7 | Quality of life scores from RECORD study
(O’Donnell et al. 2004a)
n Change in SGRQ
scores from baseline
Placebo 280 –1.79
Roflumilast 250mcg 576 –3.25
Roflumilast 500mcg 555 –3.51
SGRQ, St George’s Respiratory Questionnaire.associated with the aging process, which may also be exacerbated
by other comorbid conditions. Since dosing of roflumilast does not
appear to be affected by declining renal function (Bethke et al.
2002), it can be administered without the need for dosage
adjustment or the need to monitor renal function. 
There is an additional concern with currently available COPD
medications in patients with progressive disease who develop cor
pulmonale or pulmonary hypertension. Bronchodilators can have a
negative impact on cardiac work and thus aggravate cardiac
disease. Currently, the impact of roflumilast in patients with cor
pulmonale and pulmonary hypertension is not known; no studies
with roflumilast have included such patients. However, based on
the limited evidence of roflumilast in healthy volunteers, the drug
does not appear to have any cardiac effects. It may, therefore, be
useful in patients with cor pulmonale or pulmonary hypertension;
however, this will have to be evaluated in studies in these specific
patient populations.
Clinical potential
The preliminary data reported to date indicate that roflumilast, which
offers a unique antiinflammatory mechanism of action in an oral
formulation, is effective in decreasing symptoms associated with
moderate-to-severe COPD, and may possess clinical potential in
the management of the disease. This is supported by level 2
evidence from early reporting of two randomized controlled trials in
abstract form. At this early stage of development of the drug with
the available data, the strength of the evidence cannot be evaluated.
Although bronchodilators are currently the cornerstone of therapy
for patients with COPD, they either have to be administered by
inhalation or, in the case of theophylline, are associated with
significant toxicities and drug–drug and drug–disease interactions.
Glucocorticoids may be administered orally, but because of the
potential for adverse effects, should be reserved for acute
exacerbations. Roflumilast has not been associated with significant
drug interactions and the adverse events associated with its use
have generally been transient and mild to moderate in intensity.
Roflumilast may therefore offer the advantages of a convenient oral
treatment option without the tolerability issues associated with
glucocorticoids and theophylline. 
The early evidence therefore supports the use of roflumilast in
COPD. Its place in the stepwise approach to management of the
disease should become clearer as the randomized trial evidence is
published in full, but it has the potential to be used in early stages
of the disease, and not reserved for acute exacerbations. Of
particular interest will be additional evidence to determine if its
unique mechanism of action moderates the progression of lung
function deterioration and the clinical advantages this may offer
over the current treatments.
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